3Q Financial Reports

Wyeth

3Q Revenues: $5.1 billion (+9%)

3Q Earnings: $1.2 billion (+33%)

YTD Revenues: $15.1 billion (+8%)

YTD Earnings: $3.3 billion (+14%)

Comments: Enbrel sales, outside of the U.S. and Canada, were $378 million for the quarter and $1.1 billion YTD, increases of 37% and 38%, respectively. Prevnar sales were $510 million for the 2006 third quarter and $1.5 billion for the 2006 first nine months, increases of 30% and 32%, respectively. Effexor sales were $924 million for the 2006 third quarter and $2.8 billion for the 2006 first nine months, increases of 7% and 6%, respectively. Protonix sales were $452 million for the quarter and $1.4 billion YTD, increases of 12% and 9%, respectively. Methylnaltrexone received fast track designation from the FDA in the quarter for the treatment of post-operative ileus.

Lilly

3Q Revenues: $3.9 billion (+7%)

3Q Earnings: $873.6 million (+10%)

YTD Revenues: $11.4 billion (+6%)

YTD Earnings: $2.5 billion (+12%)*

Comments: Revenue growth in the quarter was driven by Cymbalta, Zyprexa and other newer products. Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve, collectively grew 45% to $959.7 million. Diabetes care revenue, including Humalog, Humulin, Actos and Byetta, increased 9% to $712.4 million. Gemzar sales were $354.6 million, up 6%.

*The 2005 year-to-date amounts are adjusted to exclude the $1.1 billion second-quarter product liability charge, which includes the $690 million for the previously announced Zyprexa product liability settlement as well as reserves, primarily related to Zyprexa. These charges have been offset by estimated recoveries from the company’s insurance coverage.

Baxter

3Q Revenues: $2.6 billion (+7%)

3Q Earnings: $374 million (earnings were $116 million in 3Q2005)

YTD Revenues: $7.6 billion (+3%)

YTD Earnings: $965 million (+45)

Comments: Growth in the quarter was driven by the company’s BioScience business, with sales of $1.1 billion, up 15%. Renal sales were up 6% to $519 million. In the quarter, the company signed a definitive agreement for the sale of its Transfusion Therapies business for $540 million.

Serono

3Q Revenues: $699 million (+9.5%)

3Q Earnings: $170.6 million (+20%)

Comments: Product sales grew 8% to $619.2 million. Rebif sales were up 19% to $374.8 million. Sales of Raptiva were up 81% to $18 million. Novantrone sales were $2.8 million, down 85% due to generic competition. In the quarter, the company in-licensed safinamide in early Phase III in Parkinson’s Disease.

Gilead Sciences

3Q Revenues: $748.7 million (+52%)

3Q Loss: $52.2 million* (earnings were $179 million 3Q2005)

YTD Revenues: $2.1 billion (+50%)

YTD Earnings: $475.7 million (-11%)

Comments: Product sales were a record $670.1 million for the quarter, up 43%, driven by its HIV franchise with sales up 53% to $557.3 million. Truvada sales were $309 million, up 90%. Atripla, launched in July, reached sales of $68.4 million. Sales of Hepsera totaled $55.1 million for the quarter, up 18%.

*Loss in the quarter included a charge of $355.6 million for purchased in-process research and development (IPR&D) incurred in connection with the acquisition of Corus Pharma.

Pfizer

3Q Revenues: $12.3 billion (+9%)

3Q Earnings: $3.4 billion (+112)

YTD Revenues: $35.8 billion (+3%)

YTD Earnings: $9.9 billion (+85%)

Comments: Lyrica growth continues with worldwide sales reaching $340 million in the quarter compared to $80 million in 3Q2005. Worldwide sales of Lipitor were up 15% to $3.3 billion. Worldwide sales of Celebrex reached $537 million, up 20%. Chantix for smoking-cessation and Exubera, inhalable insulin, were launched in the quarter. The withdrawal of Bextra, beginning in 2005, continued to affect revenues.